U.S. Markets open in 2 hrs 59 mins
  • S&P Futures

    3,428.50
    -4.00 (-0.12%)
     
  • Dow Futures

    28,096.00
    -38.00 (-0.14%)
     
  • Nasdaq Futures

    11,677.50
    -13.75 (-0.12%)
     
  • Russell 2000 Futures

    1,606.70
    +3.60 (+0.22%)
     
  • Crude Oil

    40.30
    +0.27 (+0.67%)
     
  • Gold

    1,919.70
    -9.80 (-0.51%)
     
  • Silver

    24.93
    -0.31 (-1.21%)
     
  • EUR/USD

    1.1840
    -0.0027 (-0.2250%)
     
  • 10-Yr Bond

    0.8160
    0.0000 (0.00%)
     
  • Vix

    29.48
    +0.13 (+0.44%)
     
  • GBP/USD

    1.3114
    -0.0029 (-0.2242%)
     
  • USD/JPY

    104.6480
    +0.0880 (+0.0842%)
     
  • BTC-USD

    12,957.90
    +1,900.89 (+17.19%)
     
  • CMC Crypto 200

    259.97
    +15.08 (+6.16%)
     
  • FTSE 100

    5,751.98
    -24.52 (-0.42%)
     
  • Nikkei 225

    23,474.27
    -92.73 (-0.39%)
     

Biofrontera entered into binding term sheet with Maruho Co., Ltd.

Leverkusen, Germany, March 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, announces that it has entered into a Binding Term Sheet with Maruho Co, Ltd, Osaka, Japan ("Maruho"), which sets out the main terms of a future license agreement. According to the Binding Term Sheet, the license agreement has the following main terms and conditions:

  • The agreement covers the commercialization of Ameluz® by Maruho in East Asia and Oceania.

  • Biofrontera AG grants Maruho an exclusive license to develop and market Ameluz® for all indications in East Asia and Oceania. Any use of the provided technology by Maruho outside these regions is expressly prohibited. Maruho is entitled, with the consent of Biofrontera, to carry out research and development within the scope of the license. Maruho will grant to Biofrontera a free and unlimited license for the results of such research and development activities by Maruho for commercialization outside East Asia and Oceania.

  • For this purpose, Maruho is to make an upfront payment to Biofrontera AG in the amount of EUR 6 million upon signing of the agreement, plus additional future payments subject to achievement of certain regulatory and sales milestones. Maruho will also make royalty payments at an initial rate of 6%, which will increase depending on sales volume and will be reduced should generic products become available in the respective countries.

  • Maruho has an obligation for commercially reasonable efforts to market Ameluz® in all countries of the territory.

  • Ameluz® will be supplied by Biofrontera to Maruho at cost plus 25%.

  • The agreement has a term of 15 years from the start of distribution in the respective country.

On February 27, 2020, Biofrontera AG obtained an independent expert assessment of the economic feasibility of the outlined terms. The findings confirm the adequacy of the terms and conditions of the agreement.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: ir@biofrontera.com